ACIP MMR Vaccine Work Group

Ms. Lynn Bahta, Work Group Chair

February 23, 2022

MMR vaccination in the United States

- Measles and rubella were eliminated in the United States in 2000 and 2004, respectively, and mumps experienced a >99% reduction in cases due to achieving and maintaining high MMR coverage
- Measles and rubella are endemic in many parts of the world and mumps is endemic worldwide. These viruses continue to cause locally acquired and importation-related cases and outbreaks.
  - In the United States during 2016 – 2021:
    - Measles cases: 13 – 1282 cases per year
    - Mumps cases: 154 – 6366 cases per year (primarily locally acquired)
    - Rubella cases: <10 cases per year (all imported)

- Currently only one licensed measles, mumps, rubella (MMR) vaccine in the U.S. (*M-M-R II*, Merck)

- ACIP MMR Work group established to evaluate **safety** and **immunogenicity** of new candidate MMR vaccine (*Priorix*, GSK), compared to M-M-R II

ACIP MMR Vaccine Work Group

- **Established**: January 2022

- **Membership:** 17 members, including ACIP voting members, liaisons, *ex-officios,* and CDC experts

- **Expertise areas**: Epidemiology, vaccine safety, infectious diseases, general medicine, pediatrics, vaccine administration/delivery, public health/surveillance, communications

ACIP MMR Work Group Terms of Reference

- **Policy topic under consideration:** Equivalency and usage of a new MMR vaccine (*Priorix*, GSK) compared to the currently licensed MMR (M-M-R II, Merck)

- **Work Group activities:**
  - Review safety and immunogenicity data for the new and currently licensed MMR vaccine.
  - Adjudicate non-inferiority of the vaccine candidate compared to currently licensed MMR vaccine.
  - Consider use for licensed indications and existing ACIP recommendations for prevention of measles, mumps and rubella.
  - Consider concomitant use with other childhood vaccines.
  - Consider interchangeability of use in the MMR vaccine series.
  - Develop MMR vaccine policy options that ACIP may consider for recommendations.

Timeline

- Today
  - Presentation of data by GSK on **safety** and **immunogenicity** of Priorix compared to M-M-R II
- January – June
  - Monthly work group meetings (additional as needed)
  - Evidence to Recommendations framework to assess the available evidence
- June 22-23
  - Work group presents policy options for consideration by ACIP*

*Pending FDA licensure

Today's agenda

- **Introduction**
  - Ms. Lynn Bahta (Work Group Chair)

- **Presentation: Overview of GSK's MMR Vaccine**
  - Dr. Remon Ebu-Elyazeed (GSK)

- **Questions**

Questions for ACIP

- Does the data presented today support the equivalency of these two vaccines?

- What additional data would you like to see to consider equivalency and interchangeability?

Work group members

ACIP members

- Lynn Bahta (chair)
- Jamie Loehr

Ex-officio/government members

- FDA: Robin Wisch

Liaisons

- AAFP: Laura Morris
- AAP: Adam Ratner
- AIM: Juventila Liko
- NAPNAP: Patsy Stinchfield

CDC Lead

- Elisabeth Krow-Lucal

CDC Participants

- Kathleen Dooling
- Mona Marin
- Paul Gastanaduy
- Paul Rota
- Tatiana Lanzieri
- Satoshi Kamidani
- Andrew Kroger
- Stephen Crooke
- Leah Shepersky

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.